Literature DB >> 25550779

microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy.

Jie Xiao1, Feng Peng2, Chao Yu1, Min Wang2, Xu Li2, Zhipeng Li1, Jianxin Jiang1, Chengyi Sun1.   

Abstract

BACKGROUND: We intended to investigate the role of microRNA 137 (miR-137) in regulating pancreatic cancer cells' growth in vitro and tumor development in vivo.
METHODS: QTR-PCR was used to examine the expression of miR-137 in pancreatic cancer cell lines and tumor cells from human patients. Lentivirual vector containing miR-137 mimic was used to overexpress miR-137 in PANC-1 and MIA PaCa-2 cells. The effects of overexpressing miR-137 on pancreatic cancer cell invasion and chemo-sensitivity to 5-fluorouracil (5-FU) were examined by cell migration and survival essays in vitro. The molecular target of miR-137, pleiotropic growth factor (PTN), was down-regulated by siRNA to examine its effects on cancer cell invasion. MIA PaCa-2 cells with endogenously overexpressed miR-137 were transplanted into null mice to examine tumor growth in vivo.
RESULTS: We found miR-137 was markedly underexpressed in both pancreatic cancer cell lines and tumor cells from patients. In cancer cells, transfection of lentivirus containing miR-137 mimic was able to markedly upregulate endogenous expression of miR-137, inhibited cancer cell invasion and increased sensitivities to chemotherapy reagent 5-FU. PTN was significantly down-regulated by overexpressing miR-137 in pancreatic cancer cells, and knocking down PTN was effective to rescue the reduced cancer cell invasion ability caused by miR-137 overexpression. More importantly, overexpressing miR-137 led to significant inhibition on tumor formation, including reductions in tumor weight and tumor size in vivo.
CONCLUSION: Our study demonstrated that miR-137 played an important role in pancreatic cancer development. It may become a new therapeutic target for gene therapy in patients suffered from pancreatic cancer.

Entities:  

Keywords:  PTN; invasion; miR-137; miRNA; pancreatic cancer

Mesh:

Substances:

Year:  2014        PMID: 25550779      PMCID: PMC4270551     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

1.  Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin.

Authors:  L Zhang; K Mizumoto; N Sato; T Ogawa; M Kusumoto; H Niiyama; M Tanaka
Journal:  Cancer Lett       Date:  1999-08-03       Impact factor: 8.679

2.  Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis.

Authors:  Francesc Balaguer; Alexander Link; Juan Jose Lozano; Miriam Cuatrecasas; Takeshi Nagasaka; C Richard Boland; Ajay Goel
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  Current status of surgery for pancreatic cancer.

Authors:  Koichi Hirata; Shinichi Egawa; Yasutoshi Kimura; Takayuki Nobuoka; Hidenori Oshima; Tadashi Katsuramaki; Toru Mizuguchi; Tomohisa Furuhata
Journal:  Dig Surg       Date:  2007-04-27       Impact factor: 2.588

5.  Recombinant lentivirus targeting the pleotrophin gene reduces pleotrophin protein expression in pancreatic cancer cells and inhibits neurite outgrowth of dorsal root ganglion neurons.

Authors:  Jun Yao; Wen-Yao Li; Shuo-Guo Li; Xiao-Shan Feng; She-Gan Gao
Journal:  Mol Med Rep       Date:  2014-01-24       Impact factor: 2.952

Review 6.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

7.  Report of incidence and mortality in China cancer registries, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

8.  Human pancreatic duct epithelial cell model for KRAS transformation.

Authors:  Nikolina Radulovich; Jia-ying Qian; Ming-Sound Tsao
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

Review 9.  miRNA dysregulation in cancer: towards a mechanistic understanding.

Authors:  Jayanth Kumar Palanichamy; Dinesh S Rao
Journal:  Front Genet       Date:  2014-03-18       Impact factor: 4.599

Review 10.  MicroRNAs: regulators of oncogenesis and stemness.

Authors:  Thales Papagiannakopoulos; Kenneth S Kosik
Journal:  BMC Med       Date:  2008-06-24       Impact factor: 8.775

View more
  19 in total

1.  MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.

Authors:  Feng-Ting Huang; Juan-Fei Peng; Wen-Jie Cheng; Yan-Yan Zhuang; Ling-Yun Wang; Chu-Qiang Li; Jian Tang; Wen-Ying Chen; Yuan-Hua Li; Shi-Neng Zhang
Journal:  Dig Dis Sci       Date:  2017-02-13       Impact factor: 3.199

2.  Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Authors:  Chiranjib Chakraborty; C George Priya Doss; Renu Sarin; Minna J Hsu; Govindasamy Agoramoorthy
Journal:  Protoplasma       Date:  2015-02-20       Impact factor: 3.356

Review 3.  Developments in miRNA gene signaling pathways in pancreatic cancer.

Authors:  Christina Vorvis; Marina Koutsioumpa; Dimitrios Iliopoulos
Journal:  Future Oncol       Date:  2016-03-17       Impact factor: 3.404

4.  Effects of targeted silencing of FOXC1 gene on proliferation and in vitro migration of human non-small-cell lung carcinoma cells.

Authors:  Sumei Chen; Shunchang Jiao; Youchao Jia; Yang Li
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

5.  The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis.

Authors:  Lawrence N Barrera; P Matthew Ridley; Camino Bermejo-Rodriguez; Eithne Costello; Pedro A Perez-Mancera
Journal:  J Physiol Biochem       Date:  2022-06-29       Impact factor: 4.158

6.  Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells.

Authors:  Wei-Hua Dong; Qin Li; Xiao-Yan Zhang; Qing Guo; Huizheng Li; Tian-Yun Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  MicroRNA-137 inhibits cell migration and invasion by targeting bone morphogenetic protein-7 (BMP7) in non-small cell lung cancer cells.

Authors:  Yan-Rong Yang; Yun-Xia Li; Xin-Yuan Gao; Sha-Sha Zhao; Shu-Zhi Zang; Zhi-Qiang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Expression of CD44 in pancreatic cancer and its significance.

Authors:  Xiao-Ping Li; Xiao-Wei Zhang; Lei-Zhen Zheng; Wei-Jian Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

9.  miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1.

Authors:  Danni Deng; Lian Xue; Naiyuan Shao; Hongtao Qu; Qiang Wang; Suinuan Wang; Xiwei Xia; Yilin Yang; Feng Zhi
Journal:  Tumour Biol       Date:  2015-10-06

10.  Hypoxia-Induced miR-137 Inhibition Increased Glioblastoma Multiforme Growth and Chemoresistance Through LRP6.

Authors:  Dong-Mei Li; Qiu-Dan Chen; Gui-Ning Wei; Jie Wei; Jian-Xing Yin; Jun-Hui He; Xin Ge; Zhu-Mei Shi
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.